Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
NCT Number: NCT07649941
The main objective of this trial is to investigate the effect of a moderate CYP 3A inducer bosentan on the pharmacokinetics of zongertinib.
Looking for future studies?
Notify Me25 year–55 year
Male
Interventional
Phase 1
Biberach, 88397, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Zongertinib
Bosentan
Time frame: up to 8 days
Time frame: up to 8 days
Time frame: up to 8 days
Boehringer Ingelheim
Industry
The Effect of Multiple Oral Doses of Bosentan on the Single Oral Dose Pharmacokinetics of Zongertinib in Healthy Male Subjects (an Open-label, Two-treatment, Two-period Fixed Sequence Trial)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04626362
Healthy
Gainesville, Florida, United States
View Trial DetailsNCT03898297
Behavior, Behavioral Symptoms
New Haven, Connecticut, United States
View Trial DetailsNCT07362251
Healthy
Trikala, Thessaly, Greece
View Trial DetailsNCT01866852
Healthy
Bethesda, Maryland, United States
View Trial Details